JP2018508218A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508218A5 JP2018508218A5 JP2017546178A JP2017546178A JP2018508218A5 JP 2018508218 A5 JP2018508218 A5 JP 2018508218A5 JP 2017546178 A JP2017546178 A JP 2017546178A JP 2017546178 A JP2017546178 A JP 2017546178A JP 2018508218 A5 JP2018508218 A5 JP 2018508218A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- amino acid
- isolated binding
- seq
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000014914 Carrier Proteins Human genes 0.000 claims 23
- 108091008324 binding proteins Proteins 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000012986 modification Methods 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 5
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims 1
- 101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 claims 1
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 208000024883 bone remodeling disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128133P | 2015-03-04 | 2015-03-04 | |
| US62/128,133 | 2015-03-04 | ||
| PCT/US2016/020779 WO2016141244A1 (en) | 2015-03-04 | 2016-03-03 | scFv-Fc DIMERS THAT BIND TRASFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508218A JP2018508218A (ja) | 2018-03-29 |
| JP2018508218A5 true JP2018508218A5 (enExample) | 2019-03-28 |
| JP6845802B2 JP6845802B2 (ja) | 2021-03-24 |
Family
ID=55538640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546178A Active JP6845802B2 (ja) | 2015-03-04 | 2016-03-03 | トランスフォーミング増殖因子β１に高親和性、アビディティおよび特異性で結合するｓｃＦｖ−Ｆｃ二量体 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10508146B2 (enExample) |
| EP (2) | EP3265484B1 (enExample) |
| JP (1) | JP6845802B2 (enExample) |
| KR (3) | KR102598790B1 (enExample) |
| CN (1) | CN107889491B (enExample) |
| AR (1) | AR103839A1 (enExample) |
| AU (1) | AU2016226097B2 (enExample) |
| BR (1) | BR112017018767A2 (enExample) |
| ES (1) | ES3014555T3 (enExample) |
| IL (1) | IL254238B (enExample) |
| MX (2) | MX2017011251A (enExample) |
| RU (1) | RU2733286C2 (enExample) |
| SG (2) | SG10201912449UA (enExample) |
| TW (1) | TWI726870B (enExample) |
| WO (1) | WO2016141244A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CN112500491B (zh) * | 2020-12-18 | 2022-04-08 | 深圳市迈加瑞生物技术有限公司 | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 |
| CN116179493A (zh) * | 2021-09-29 | 2023-05-30 | 成都美杰赛尔生物科技有限公司 | 敲除两种免疫检测点基因的免疫细胞及其制备方法与应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
| ES2146552B1 (es) * | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| EP1486560A3 (en) | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| CA2581787A1 (en) | 2004-09-22 | 2006-04-06 | Genzyme Corporation | Use of tgf-b antagonists to limit nephrotoxicity of immunosuppressive agents |
| US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| RS51845B (sr) * | 2005-04-22 | 2012-02-29 | Eli Lilly And Company | Specifična tgf beta 1 antitela |
| WO2007076391A1 (en) * | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
| GEP20135917B (en) | 2006-03-17 | 2013-09-10 | Biogen Idec Inc | Stabilized polypeptide compositions |
| AU2007227963A1 (en) | 2006-03-23 | 2007-09-27 | Kyowa Hakko Kirin Co., Ltd. | Agonist antibody to human thrombopoietin receptor |
| PL2918288T3 (pl) | 2006-10-03 | 2018-02-28 | Genzyme Corporation | Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej |
| JP2012531885A (ja) | 2008-07-02 | 2012-12-13 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | Ｉｌ６免疫治療剤 |
| ES2702049T3 (es) | 2009-04-24 | 2019-02-27 | Univ Vanderbilt | Inducción anti-TGF-beta de crecimiento óseo |
| EP2655624B1 (en) * | 2010-12-23 | 2017-11-29 | Biogen MA Inc. | Linker peptides and polypeptides comprising same |
| TWI588156B (zh) | 2011-03-28 | 2017-06-21 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| EP3954704A1 (en) | 2011-06-03 | 2022-02-16 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
| AU2013293092A1 (en) | 2012-07-23 | 2015-02-26 | Zymeworks Inc. | Immunoglobulin constructs comprising selective pairing of the light and heavy chains |
| BR112015021595A2 (pt) * | 2013-03-11 | 2017-10-10 | Genzyme Corp | anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno |
| EA032327B1 (ru) | 2013-03-20 | 2019-05-31 | Джензим Корпорейшн | Способы лечения несовершенного остеогенеза |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
-
2016
- 2016-03-02 TW TW105106243A patent/TWI726870B/zh active
- 2016-03-03 EP EP16710059.3A patent/EP3265484B1/en active Active
- 2016-03-03 CN CN201680025665.5A patent/CN107889491B/zh active Active
- 2016-03-03 EP EP24220330.5A patent/EP4527850A3/en active Pending
- 2016-03-03 US US15/555,499 patent/US10508146B2/en active Active
- 2016-03-03 KR KR1020177027371A patent/KR102598790B1/ko active Active
- 2016-03-03 MX MX2017011251A patent/MX2017011251A/es unknown
- 2016-03-03 WO PCT/US2016/020779 patent/WO2016141244A1/en not_active Ceased
- 2016-03-03 KR KR1020257000711A patent/KR20250009587A/ko active Pending
- 2016-03-03 KR KR1020237037758A patent/KR102754133B1/ko active Active
- 2016-03-03 RU RU2017134042A patent/RU2733286C2/ru active
- 2016-03-03 AR ARP160100559A patent/AR103839A1/es unknown
- 2016-03-03 JP JP2017546178A patent/JP6845802B2/ja active Active
- 2016-03-03 SG SG10201912449UA patent/SG10201912449UA/en unknown
- 2016-03-03 SG SG11201707105TA patent/SG11201707105TA/en unknown
- 2016-03-03 AU AU2016226097A patent/AU2016226097B2/en not_active Ceased
- 2016-03-03 BR BR112017018767A patent/BR112017018767A2/pt not_active IP Right Cessation
- 2016-03-03 ES ES16710059T patent/ES3014555T3/es active Active
-
2017
- 2017-08-31 IL IL254238A patent/IL254238B/en unknown
- 2017-08-31 MX MX2022007456A patent/MX2022007456A/es unknown
-
2019
- 2019-10-30 US US16/669,211 patent/US11325971B2/en active Active
-
2022
- 2022-04-04 US US17/713,087 patent/US11976112B2/en active Active
-
2024
- 2024-04-04 US US18/627,131 patent/US12473356B2/en active Active